Sign in
4

Changes in Ownership

Trevi Therapeutics, Inc. Filed Acc 0001209191-22-040287

Options or other derivatives

  • Chief Development Officer acquired 48,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Forbes William P Chief Development Officer 2022-06-29 Grant or award · Performance Stock Options (right to buy) +48,000 48,000 D: show line 1 in the form
Loading xslF345X03/doc4.xml…